So far, NVS is the only Big Pharma that hasn’t lowered sales and EPS guidance to account for ObamaCare. Why hasn’t it? Simple arithmetic: 60% of NVS’ sales come from the pharma division and only one-third half of that comes from the US
The other side of the coin - NVS is much more exposed to Europe/Euro and might face headwind from the crisis there.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.